|United States Patent||7,960,350|
|Robledo||June 14, 2011|
Embodiments of the invention disclosed herein relate to methods of preventing and/or ameliorating one or more symptoms associated with an eye disease such as dry eye syndrome, cataracts of the eye and nuclear sclerosis of the eye lens by administering to a subject a therapeutically effective amount of N.alpha.-acetyl-L-histidine. Additionally, provided herein are pharmaceutical compositions comprising N.alpha.-acetyl-L-histidine. Kits for preventing and/or ameliorating one or more symptoms associated with an eye disease by administering a pharmaceutical composition comprising N.alpha.-acetyl-L-histidine are also disclosed.
|Inventors:||Robledo; Emilio (Tijuana, MX)|
ADER Enterprises, Inc.
|Filed:||October 21, 2004|
|Application Number||Filing Date||Patent Number||Issue Date|
|Current U.S. Class:||514/21.91 ; 514/400|
|Current International Class:||A61K 38/05 (20060101); A01N 43/50 (20060101); A61K 31/415 (20060101)|
|Field of Search:||514/21.91,400|
|5013556||May 1991||Woodle et al.|
|5213804||May 1993||Martin et al.|
|5225212||July 1993||Martin et al.|
|5356633||October 1994||Woodle et al.|
|5512592||April 1996||Zaloga et al.|
|5540935||July 1996||Miyazaki et al.|
|5543152||August 1996||Webb et al.|
|5556948||September 1996||Tagawa et al.|
|5705188||January 1998||Junichi et al.|
|6159485||December 2000||Yu et al.|
|6281192||August 2001||Leahy et al.|
|6629970||October 2003||Bagrov et al.|
Morris Baslow, Function of the N-Acetyl-L-Histidine System in the Vertebrate Eye, 10 J. Mol. Neurosci. 193 (1998). cited by examiner .
Shulin Ding, Recent Developments in Ophthalmic Drug Delivery, 1 PSTT 328 (Nov. 1998). cited by examiner .
MayoClinic.com, Cataracts Symptoms, available at http://www.mayoclinic.com/health/cataracts/DS00050/DSECTION=symptoms. cited by examiner .
Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics, U.S. Department of Health and Human Services, Food and Drug Administration, May 1999. cited by examiner .
Leo Chylack, et al, Classification of Human Senile Cataractous Change by the American Cooperative Cataract Research Group (CCRG) Method, 25 Inv. Ophthalmol. Vis. Sci. 174, (1984). cited by examiner .
Mark Babizhayev, Antioxidant Activity of L-Carnosine, a Natural Histidine-Containing Dipeptide in Crystalline Lens, 1004 Biochim. Biophysica Acta 363 (1989). cited by examiner .
International Search Report from PCT/US04/35021 dated Oct. 11, 2005. cited by other .
Written Opinion of the International Searching Authority from PCT/US04/35021 dated Oct. 11, 2005. cited by other .
Babizhayev, 1989 Biochemica et Biophysica Acta 1004:363-371. cited by examiner .
Babizhayev, 1996 Clinica Chimica Acta 254:1-21. cited by examiner .
Biros, et al. 2000. J. Am. Vet. Med. Assoc. 216:1780-6. cited by examiner .
Statistics on Vision Impairment: A Resource Manual, 5.sup.th edition, Apr. 2002. cited by examiner .
Mican, Phil, "An interview with Mark Babizhayev Ph.D. about the development of NAC eye-drops" obtained from: http://www.antiaging-systems.com/ARTICLE-490/babizhayev-can-c-development- .htm, on Oct. 18, 2010. cited by other .
"Eye Medications" obtained from: http://www.uic.edu/com/eye/LearningAboutVision/EyeFacts/MedicineForEyes.s- html, on Oct. 18, 2010, dated Jan. 1, 1992. cited by other.